肾移植术后依维莫司在免疫抑制治疗中的有效性和安全性评价

被引：3

作者：

毛棉 ^{[1
]}

吴斌 ^{[2
]}

蒋学华 ^{[1
]}

王凌 ^{[1
]}

机构：

[1] 四川大学华西药学院临床药学研究中心

[2] 四川大学华西医院

来源：

中国医院药学杂志 | 2013年 / 33卷 / 06期

关键词：

依维莫司; 肾移植; Meta分析; 有效性; 安全性;

D O I：

10.13286/j.cnki.chinhosppharmacyj.2013.06.019

中图分类号：

R699 [泌尿及男性生殖系外科学];

学科分类号：

100210 [外科学];

摘要：

目的:系统的评价肾移植术后依维莫司免疫抑制效果和安全性。方法:计算机检索Cochrane图书馆、SCI、EM-BASE、PubMed、CNKI、VIP、CBM和万方数据库,检索时间均从建库至2012年1月,纳入肾移植术后使用依维莫司进行免疫抑制治疗的随机对照试验(RCT)。在评价纳入研究的方法学质量和提取有效数据后,采用RevMan 5.0进行Meta分析。结果:共纳入7个RCT,包括1 998例患者,质量评价结果显示5个研究为A级、2个为B级。Meta分析结果显示:依维莫司对比阳性药物钙调磷酸酶抑制剂(CNI)、吗替麦考酚酯急性排斥反应发生率、肌酐清除率、患者存活率和移植物存活率差异均无统计学意义。结论:基于当前临床证据,肾移植术后依维莫司疗效可靠;远期结果有待进一步研究。

引用

收藏

页码：492 / 496

页数：5

相关论文

共 11 条

[1]

Conversion of Long-Term Kidney Transplant Recipients From Calcineurin Inhibitor Therapy to Everolimus: A Randomized, Multicenter, 24-Month Study [J].

Holdaas, Hallvard ;

Rostaing, Lionel ;

Seron, Daniel ;

Cole, Edward ;

Chapman, Jeremy ;

Fellstrom, Bengt ;

Strom, Erik H. ;

Jardine, Alan ;

Midtvedt, Karsten ;

Machein, Uwe ;

Ulbricht, Bettina ;

Karpov, Alexander ;

O'Connell, Philip J. .

TRANSPLANTATION, 2011, 92 (04) :410-418

[2]

Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial [J].

Budde, Klemens ;

Becker, Thomas ;

Arns, Wolfgang ;

Sommerer, Claudia ;

Reinke, Petra ;

Eisenberger, Ute ;

Kramer, Stefan ;

Fischer, Wolfgang ;

Gschaidmeier, Harald ;

Pietruck, Frank .

LANCET, 2011, 377 (9768) :837-847

[3]

Everolimus Plus Reduced-Exposure CsA versus Mycophenolic Acid Plus Standard-Exposure CsA in Renal-Transplant Recipients [J].

Silva, H. Tedesco, Jr. ;

Cibrik, D. ;

Johnston, T. ;

Lackova, E. ;

Mange, K. ;

Panis, C. ;

Walker, R. ;

Wang, Z. ;

Zibari, G. ;

Kim, Y. S. .

AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 (06) :1401-1413

[4]

Switch of immunosuppression from cyclosporine A to everolimus: impact on pulse wave velocity in stable de-novo renal allograft recipients [J].

Seckinger, Joerg ;

Sommerer, Claudia ;

Hinkel, Ulrich-Paul ;

Hoffmann, Oskar ;

Zeier, Martin ;

Schwenger, Vedat .

JOURNAL OF HYPERTENSION, 2008, 26 (11) :2213-2219

[5]

Target of rapamycin inhibitors (Sirolimus and Everolimus) for primary immunosuppression of kidney transplant recipients: A systematic review and meta-analysis of randomized trials [J].

Webster, Angela C. ;

Lee, Vincent W. S. ;

Chapman, Jeremy R. ;

Craig, Jonathan C. .

TRANSPLANTATION, 2006, 81 (09) :1234-1248

[6]

Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients [J].

Vítko, S ;

Margreiter, R ;

Weimar, W ;

Dantal, J ;

Kuypers, D ;

Winkler, M ;

Oyen, O ;

Viljoen, HG ;

Filiptsev, P ;

Sadek, S ;

Li, YL ;

Cretin, N ;

Budde, K .

AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 (10) :2521-2530

[7]

Everolimus versus mycophenolate mofetil in the prevention of rejection in de Novo renal transplant recipients: A 3-year randomized, multicenter, phase III study [J].

Lorber, MI ;

Mulgaonkar, S ;

Butt, KMH ;

Elkhammas, E ;

Mendez, R ;

Rajagopalan, PR ;

Kahan, B ;

Sollinger, H ;

Li, YL ;

Cretin, N ;

Tedesco, H .

TRANSPLANTATION, 2005, 80 (02) :244-252

[8]

Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients [J].

Vitko, S ;

Margreiter, R ;

Weimar, W ;

Dantal, J ;

Viljoen, HG ;

Li, YL ;

Jappe, A ;

Cretin, N .

TRANSPLANTATION, 2004, 78 (10) :1532-1540

[9]

Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era [J].

Meier-Kriesche, HU ;

Schold, JD ;

Srinivas, TR ;

Kaplan, B .

AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (03) :378-383

[10]

Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling [J].

Abraham, RT .

CURRENT OPINION IN IMMUNOLOGY, 1998, 10 (03) :330-336